A Novel Camptothecin Derivative Incorporated in Nano-Carrier Induced Distinguished Improvement in Solubility, Stability and Anti-tumor Activity Both In Vitro and In Vivo
An oil/water nanoemulsion was developed in the present study to enhance the solubility, stability and anti-tumor activity of a novel 10-methoxy-9-nitrocamptothecin (MONCPT).
Materials and Methods
MONCPT nanoemulsion was prepared using Lipoid E80 and cremophor EL as main emulsifiers by microfluidization. The droplet size of the nanoemulsion was measured by dynamic light scattering. In vitro drug release was monitored by membrane dialysis. Kinetics of MONCPT transformed into carboxylic salt was performed in phosphate buffer at different pH. Hemolysis of MONCPT nanoemulsion was conducted in rabbit erythrocytes. Solubilization character of MONCPT in nanoemulsion was experimented using Nile red as a solvatochromic probe. In vitro cytotoxicity of the nanoemulsion was measured in A549 and S180 cells using Sulforhodamine B protein stain method, and suppression rate of tumor growth was investigated in S180-bearing mice. The cell cycle effects of MONCPT nanoemulsion on S180 cells were analyzed by flow cytometry. Distribution of the nanoemulsion in A549 cells and S180-bearing mice were also investigated by fluorescence image.
MONCPT is incorporated in the nanoemulsion in form of lactone with concentration of 489 µg/ml, more than 200 folds higher than that in water. Experiments using Nile red as a solvatochromic probe indicated that more MONCPT might be located in the interfacial surfactant layer of the nanoemulsion than that in discrete oil droplet or continuous aqueous phase. Nanoemulsion could release MONCPT in a sustained way, and it was further shown to notably postpone the hydrolysis of MONCPT with longer hydrolysis half-life time (11.38 h) in nanoemulsion at pH 7.4 than that of MONCPT solution (4.03 h). No obvious hemolysis was caused by MOCPT nanoemulsion in rabbit erythrocytes. MONCPT nanoemulsion showed a marked increase in cytotoxic activity, 23.6 folds and 28.6 folds in S180 cells and A549 cells respectively via arresting the cell at G2 phase, compared to that induced by MONCPT injection. It correlated well to the in vivo anti-tumor activity of MONCPT nanoemulsion with suppression rate of 93.6%, while that of MONCPT injection was only 24.2% at the same dosage. Moreover, nanoemulsion exhibited enhanced capability of delivering drug into malignant cell’s nucleus in vitro and induced drug accumulation in tumor in S180-bearing mice using in vivo imaging.
The nanoemulsion prepared exhibited an improved MONCPT solubility, stability and anti-tumor activity, providing a promising carrier for cancer chemotherapy using MONCPT.
KEY WORDS10-Methoxy-9-nitrocamptothecin (MONCPT) anti-tumor fluorescence nanoemulsion nile red
The study was supported in part by Scientific Research Fund of Ministry of Health-Medical Science Critical Technological Program of Zhejiang Province, by the Health Bureau of Zhejiang Province Foundation (No. WKJ2008-2-029), Zhejiang Provincial Program for the Cultivation of High-level Innovative Health Talents, and Zhejiang Provincial Natural Science Foundation of China (Y207259).
- 2.O. Lavergne, and D. C. Bigg. The other camptothecins: recent advances with camptothecin analogues other than irinotecan and topotecan. Bull. Cancer. 12:51–58 (1998).Google Scholar
- 6.M. Gao, K. D. Miller, G. W. Sledgeb, and Q. H. Zheng. Radiosynthesis of carbon-11-labeled camptothecin derivatives as potential positron emission tomography tracers for imaging of topoisomerase I in cancers. Bioorg. Med. Chem. Lett. 15:3865–3869 (2005). doi: 10.1016/j.bmcl.2005.05.108.PubMedCrossRefGoogle Scholar
- 11.R. P. Hertzberg, M. J. Caranfa, K. G. Holden, D. R. Jakas, G. Gallagher, M. R. Mattern, S. M. Mong, J. O. Bartus, R. K. Johnson, and W. D. Kingsbury. Modification of the hydroxy lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity. J. Med. Chem. 32:715–720 (1989). doi: 10.1021/jm00123a038.PubMedCrossRefGoogle Scholar
- 13.P. P. Constantinides, K. J. Lambert, A. K. Tustian, B. Schneider, S. Lalji, W. Ma, B. Wentzel, D. Kessler, D. Worah, and S. C. Quay. Formulation development and antitumor activity of filter-sterilizable emulsion of paclitaxel. Pharm. Res. 17:175–182 (2000). doi: 10.1023/A:1007565230130.PubMedCrossRefGoogle Scholar
- 18.L. A. Pires, R. Hegg, C. J. Valduga, S. R. Graziani, D. G. Rodrigues, and R. C. Maranhao. Use of cholesterol-rich nanoparticles that bind to lipoprotein receptors as a vehicle to paclitaxel in the treatment of breast cancer: pharmacokinetics, tumor uptake and a pilot clinical study. Cancer Chemother Pharmacol., in press (2008) http://www.springerlink.com/content/t1452120506h7327/.